Skip to main content

Molecular Biology

Leukemias & Lymphomas

Let’s dive into one of the most impactful areas of clinical molecular testing: the world of hematologic malignancies. Leukemias and lymphomas are cancers of the blood and lymph systems, respectively. They arise when the normal, tightly controlled process of creating blood cells goes haywire. A single cell acquires a genetic “mistake,” allowing it to divide uncontrollably and crowd out the healthy cells

Molecular diagnostics acts as our high-tech detective squad. We go into the patient’s cells and look for the specific broken pieces of the genetic blueprint that are causing the cancer. Finding these specific mistakes is not just academic; it often tells us the exact diagnosis, predicts how the disease will behave (prognosis), and, most excitingly, points us directly to a targeted therapy that can fix the problem

We’ll look at this in two major categories: finding the specific “smoking gun” mutations and identifying the unique “fingerprint” of a cancerous clone

Specific Translocations & Fusion Genes: The Smoking Gun

In many leukemias, the catastrophic event is a chromosomal translocation. This is when two different chromosomes break and accidentally swap pieces. When this happens, it can slam two previously unrelated genes together, creating a brand-new, abnormal hybrid gene called a fusion gene. This fusion gene often produces a fusion protein that acts like a gas pedal stuck to the floor, driving constant cell division

The Poster Child: CML and the Philadelphia Chromosome

  • The Cancer: Chronic Myeloid Leukemia (CML)
  • The Event: A translocation between chromosome 9 and chromosome 22, written as t(9;22)
  • The Genes: The ABL1 gene from chromosome 9 fuses with the BCR gene on chromosome 22
  • The Result: This creates the notorious BCR-ABL1 fusion gene. This gene sits on the new, shortened chromosome 22, famously known as the Philadelphia (Ph) chromosome. The BCR-ABL1 fusion protein is a hyperactive tyrosine kinase that signals the cell to grow and divide nonstop
  • The Role of Molecular Testing
    • Diagnosis: Detecting the BCR-ABL1 fusion transcript (the mRNA message) using Reverse Transcriptase PCR (RT-PCR) is the gold standard for diagnosing CML
    • Monitoring Therapy: This is where molecular testing shines. Patients are treated with Tyrosine Kinase Inhibitors (TKIs) like imatinib (Gleevec) that specifically block the BCR-ABL1 protein. We use Quantitative real-time PCR (qPCR) to measure the amount of the BCR-ABL1 transcript in the patient’s blood over time. This is essentially a “molecular load” test, analogous to a viral load. The goal is to achieve a Major Molecular Response (MMR), where the level of the cancer-causing gene drops by at least 1,000-fold. This guides treatment and provides an early warning if the cancer is relapsing

Other Key Translocations

  • Acute Promyelocytic Leukemia (APL): Caused by t(15;17), which creates the PML-RARA fusion gene. This is another home-run for targeted therapy. The abnormal protein messes with retinoic acid signaling. The treatment? A form of Vitamin A called all-trans-retinoic acid (ATRA), which directly helps fix the protein’s function. Detecting the PML-RARA transcript is crucial for diagnosis
  • Acute Lymphoblastic Leukemia (ALL): Many different translocations can cause ALL. Identifying the specific fusion (e.g., t(12;21) in pediatric ALL, or even a Philadelphia chromosome-like translocation) is critical for risk stratification—determining if the patient has a good- or poor-prognosis version of the disease, which dictates the intensity of chemotherapy

Clonal Gene Rearrangements: The Unique Fingerprint

This is a different, but equally clever, application. To understand it, we first have to appreciate a beautiful bit of normal biology

  • Normal Immunity: Your body contains millions of different B-cells and T-cells (lymphocytes). Each one must recognize a different potential invader (a virus, bacterium, etc.). To create this incredible diversity, each developing lymphocyte shuffles the DNA of its antigen receptor genes (the immunoglobulin/Ig genes in B-cells, and T-cell receptor/TCR genes in T-cells). This process is called V(D)J recombination. The end result is a healthy, polyclonal population where almost every lymphocyte has its own unique gene rearrangement, like a crowd of people all speaking different languages
  • The Cancerous State: What happens in a lymphoma or lymphocytic leukemia? A single B-cell or T-cell with one specific gene rearrangement becomes cancerous and starts dividing. All of its daughter cells are identical clones, and they all share the exact same unique rearranged Ig or TCR gene. This creates a monoclonal population—like a crowd where everyone is chanting the exact same phrase over and over

Molecular Detection of Clonality

We design PCR primers that flank the rearranged region of the Ig or TCR genes. We run the PCR on DNA from the patient’s blood or lymph node tissue

  • Polyclonal Result (Normal/Reactive): The primers amplify thousands of different-sized fragments from the thousands of different normal lymphocytes. On a capillary electrophoresis trace, this looks like a broad, “smeary” Gaussian curve. This is evidence against cancer
  • Monoclonal Result (Cancer): The primers overwhelmingly amplify one single fragment size from the massive population of cancer clones. On the capillary trace, this produces a single, sharp, dominant peak. This is strong evidence for a leukemia or lymphoma

Clinical Uses of Clonality Testing

  • Diagnosis: Helps a pathologist distinguish a malignant lymphoma from a benign, reactive process (like an infected lymph node) that might look similar under the microscope
  • Minimal Residual Disease (MRD) Monitoring: This is a huge application. Once a patient is diagnosed, we can sequence their unique monoclonal “fingerprint.” After treatment, we can use highly sensitive methods (like qPCR or Next-Generation Sequencing) with patient-specific primers to hunt for even a tiny number of remaining cancer cells. The re-emergence of that specific clonal peak is the earliest sign of relapse, often appearing months before a clinical relapse would be noticed

Key Terms

  • Translocation: A chromosomal abnormality where a piece of one chromosome breaks off and attaches to another chromosome. This can create disease-causing fusion genes
  • Fusion Gene: An abnormal hybrid gene created by a translocation that joins two previously separate genes. The protein product of a fusion gene often drives uncontrolled cell growth (e.g., BCR-ABL1)
  • Philadelphia Chromosome (Ph): The small, abnormal chromosome 22 that results from the t(9;22) translocation and contains the BCR-ABL1 fusion gene. It is the hallmark of Chronic Myeloid Leukemia (CML)
  • Clonality: A state in which a population of cells is derived from a single common ancestor. In oncology, detecting a monoclonal population of lymphocytes is evidence of a leukemia or lymphoma
  • Gene Rearrangement: The normal physiological process (V(D)J recombination) by which developing B-cells and T-cells shuffle their antigen receptor genes (Ig and TCR) to create diversity. This process is exploited to detect clonality
  • Minimal Residual Disease (MRD): The small number of cancer cells that remain in a patient during or after treatment when they are in clinical remission. Molecular detection of MRD is used to predict relapse
  • Polyclonal: Describes a population of cells (e.g., lymphocytes) arising from many different ancestral cells, resulting in a wide variety of gene rearrangements. This is characteristic of a normal, healthy immune response